SLC16A1 and cancer: Considering a higher lactate level was observed in KIC-treated macrophages, our results imply that the antitumor benefits of targeting MCT1 may partially be due to the blocked uptake of cancer-derived BCKAs or KIC-triggered lactate by surrounding immune cells.